Biofabri, Bharat Biotech sign technology transfer agreement for MTBVAC TB vaccine
Biofabri and Bharat Biotech International Limited signed a technology transfer agreement to ensure the MTBVAC TB vaccine is manufactured in India. After successful Phase I and II trials, BBIL plans a Phase III study starting in early 2026.
Hyderabad: Biofabri, a global human vaccine development company that is part of the Zendal group, and Bharat Biotech International Limited (BBIL), on Monday signed a Technology Transfer Agreement, aimed at improving access to TB vaccines.
The technology transfer has already begun to ensure BBIL’s manufacturing readiness by the time of MTBVAC licensure in India. The MTBVAC is a highly promising TB vaccine currently in the final stages of clinical trials and is being hailed as a potential breakthrough.
The agreement will ensure that MTBVAC is accessible, affordable and equitably available, particularly in countries with the highest tuberculosis burden, a press release from BBIL said.
MTBVAC has undergone Phase I and II clinical trials in India. The vaccine candidate has demonstrated safety and immunogenicity. Based on these initial results, BBIL is preparing for a pivotal Phase III vaccine efficacy study, which is expected to begin recruiting participants in the first quarter of 2026.
